

" References "

♦**Agraharkar M, Safirstein RL and Greenberg A (2001):**

Pathophysiology of acute renal failure In: Primer on kidney disease, 3rd Ed, San Diego, Calif, academic press, p 243- 86.

♦**Agrawal M and Swartz R (2000):**

Acute renal failure.

Am Fam Physician, 61: 2077- 88.

♦**Alexandre DA, Gottschall C and Manica A (2005):**

Effectiveness of acetylcysteine in prevention of contrast nephropathy.

The journal of invasive cardiology, 17 (2): 80-84.

♦**Allen SJ, Penugonda SP and Baker RC (2003):**

Low dose dopexamine does not alter subclinical renal indices following cardiac surgery.

European Journal of Anaesthesiology, 20 (suppl 29): A28.

♦**Andreoloi SP (2004):**

Acute renal failure in newborn.

Semin. Perinatol, 28(2): 112-23.

♦**Andreoloi SP (2004):**

Clinical evaluation and management of acute renal failure In: Pediatric nephrology, Lippincott Williams& Wilkins, p 1233.

♦**Aronoff GR (1999):**

Drug prescribing in renal failure, 4th Ed, Philadelphia, PA: American college of physicians.

◆Aronson S, Kellen M and Roizen M (1994):

Predictive and diagnostic tests of RF: A review.
Anest Analg, 78: 134- 142.

◆Aronson S, Wilson WC (2001):

Oliguria a sign of renal success or impending renal failure?
Anesthesiol Clin North Am, 19: 841.

◆Azizzadeh A, Sanchez LA and Miller CC (2006):

Glomerular filtration rate is a predictor of mortality after endovascular abdominal aortic aneurysm repair.
J Vasc Surg, 43(1): 14-8.

◆Barozzi L, Valentino M and Santoro A (2007):

Renal ultrasonography in critically ill patient.
Crit Care Med, vol 35: S 198-S 205.

◆Bellomo R, Kellum JA and Ronco C (2007):

Defining and classifying acute renal failure from advocacy to consensus and validation of the RIFLE criteria.
Intensive Care Med, 33(3):409-13.

◆Berger CS and Malpas CS (1998):

Modelling of the dynamic relationship between arterial pressure, renal sympathetic nerve activity and renal blood flow in conscious rabbit.
The Journal of Experimental Biology, 201: 3425- 3430.

◆Bonventre JV and Zuke A (2004):

Ischemic acute renal failure: an inflammatory disease.
Kidney Int, vol 66: 480- 486.

♦**Briguori C, Manganelli F and Scarpato P (2002):**

Acetylcystein and contrast agent- associated nephropathy.
J Am Coll Cardiol, vol 40: 298- 303.

♦**Brunton LL, Lazo JS and Parker KL (2006):**

Inhalational anesthetic, drugs acting on central nervous system, Goodman and Gilman's : The pharmacological basis of therapeutics, 11st Ed, Mc Graw Hill.

♦**Bunchman TE, McBryde KD and Mottes TE (2001):**

Pediatric acute renal failure: outcome by modality and disease.
Pediatric Nephrol, 16: 1076- 1071.

♦**Burnier M (2001):**

Cardiovascular drugs: Angiotensin II type 1 receptor blockers.
Circ ulation, 103- 104.

♦**Caldwell HK and Young WS (2006):**

Oxytocin and vasopressin: Genetics and behavioral implications In: Handbook of Neurochemistry and Molecular Neurobiology: Neuroactive proteins and peptides, 3rd Ed, Berlin Springer, p: 573- 607.

♦**Canaud B, Chenine L and Leray- Morgues H (2006):**

Residual renal function and dialysis modality: Is it really beneficial to preserve residual renal function in dialysis patient?
Nephrol, vol 11, issue 4, p292- 296.

♦**Chadban SJ and Atkins RC (2005):**

Glomerulonephritis.
Lancet, vol 365: 1797- 1806.

♦Chan JM, Williams DM and Roth KS (2002):

Kidney failure in infant and children.

Pediatric in review, 23: 47- 60.

♦Cittanova ML, Zubicki A and Savu C (2001):

The chronic inhibition of angiotensin converting enzyme impairs postoperative renal function.

Anesth Analg, 93: 1111- 5.

♦Coleman JE and Watson AR (2008):

Nutritional support for the child with acute renal failure.

Journal of Human Nutrition and Dietetics, vol 5, issue 2: p 99- 105.

♦Cranney A, Horsley T and O' Donnell S (2007):

Effectiveness and safety of vitamin D in relation to bone health.

Evid Rep Technol Assess, 158: 1-235.

♦Cromwell PF, Munn N and Wynne Z (2005):

Evaluation and management of hypertension in children and adolescent (part2): Evaluation and management.

J Ped Health Care, vol 19, issue 5: p 309- 313.

♦Dean M (2004):

Opioids in renal failure and dialysis patients.

J Pain Symptom Manag, 28: 497- 504.

♦Denker BM and Brenner BM (2006):

Assessment of glomerular filtration rate, Harrison's principles of internal medicine, Mc Graw Hill.

♦Dibona FG (2001):

Differentiation of vasoactive renal sympathetic nerve fibers.
Acta Physiologica Scandinavica, vol 168, issue 1: p 199-200.

♦Diercks DB, Shumaik GM and Harrigan RA (2004):

Electrocardiography manifestation: Electrolyte abnormalities.
J Emerg Med, 27: 153-160.

♦Dundee JW and Hassard TH (2007):

The influence of hemoglobin and plasma urea levels on induction dose of thiopentone.
Anesthesia, vol 38, issue 1: p 26- 28.

♦Durnin C, Hind ID and Wickens MM (2001):

Pharmacokinetics of oral immediate- release –hydromorphone (Diluadid IR) in subjects with renal impairment.
Proc West Pharmacol Soc, 44: 81- 82.

♦Eger EI, Koblin DD and Bowland T (1997):

Nephrotoxicity of sevoflurane versus desflurane anesthesia in volunteers.
Anesth Analg, 84: 160- 164.

♦Fienfield DA, Bargouthi H and Niaz Q (2002):

Massive and disproportionate elevation of blood urea nitrogen in acute azotemia.
Int Urol Nephrol, 34 (1): 143- 5.

♦Fischereder M, Hoffman U and Kruger B (2004):

The value of N-acetylcysteine in the prevention of radiocontrast agent induced nephropathy seemed questionable.

J Am Soc Nephrol, 15: 407- 410.

♦**Ganong WF (2001):**

Review of medical physiology, 20th Ed, Mc Graw Hill.

♦**Garwood S, Swamidoss CP and Davis EA (2003):**

A case series of low dose fenoldopam, in seventy cardiac surgical patients at increased risk of renal dysfunction.

J Cardiothorac Vasc Anesth, 17: 17- 21.

♦**Glass RB (2008):**

Caffey's Pediatric Diagnostic Imaging, 11th Ed, Am J Roentgenol, 191: 76.

♦**Goldfarb DA (2002):**

Etiology, pathogenesis and management of renal failure, In PC Walsh et al, eds, Campbell's Urology, 8th Ed, p 272- 306, Saunders WB.

♦**Goligorsky MS, Iijima K and Krivenko Y (1997):**

Role of mesangial cells in macula densa to afferent information transfer. Clin Exp Pharmacol Physiol, 24(7): 527- 531.

♦**Gouyon JB and Guignard JP (2000):**

Management of acute renal failure in newborn.
Pediat Nephrol, 14(10-11): 1037- 44.

♦**Gray H (2000):**

The urinary organs In: Anatomy of the human body, 20th Ed, reedited :
Warrin H Lewis.

◆Grayson AD, Khater M and Jackson M (2003):

Valvular heart operations is an independent risk factor for acute renal failure.

The Annals of Thoracic Surgery, 75(6): 1829- 1835.

◆Guyton A and Hall JE (2000):

Renal diseases, In: Textbook of medical physiology, 16th Ed, Saunders.

◆Harris JW and Daniel RB (2001):

Anatomy of renal system, Sabiston textbook of surgery, 16th Ed, Saunders.

◆Haynes SR and Morton NS (2007):

Prolonged neuromuscular blockage with vecuronium in a neonate with renal failure.

Anesth, 45(9): 743- 745.

◆Hickling K, Bellomo R and Chapman M (2000):

Low dose of dopamine in patients with early renal dysfunction: A placebo- controlled randomized trial. Australian and Newzealand Intensive Care Society (ANZICS) clinical trial group.

Lancet, 356: 2139- 43.

◆Hohne C, Donaubaue B and Kaisers U (2004):

Opioids during anesthesia in renal and liver failure.

Der Anaesthesist, 53(3): 291- 303.

◆Homel P, Ronco C and Bellomo R (2000):

Effect of different doses in continuous venovenous hemofiltration on outcomes of acute renal failure: a prospective randomized trial.

Lancet 355: 26- 30.

♦**Hsu CY, Ordonez JD and Chertow GM (2008):**

The risk of acute renal failure in patients with chronic kidney disease.

Kidney Int, 74(1): 101- 107.

♦**Jain RK, Agarwal RC and Yadava A (2008):**

Prevention of perioperative renal failure.

Indian Journal of Anesth, 52 (1):38- 43.

♦**Jarnberg PO (2004):**

Renal protective strategies in perioperative period.

Best Practical Research In Anaesthesiology, 4: 645-60.

♦**Javed MA, Sial MH and Lingawi S (2005):**

Etiology of posterior reversible encephalopathy syndrome.

Pak J Med Sci, 21 (2): 149- 54.

♦**Jones DR and Lee HT (2007):**

Protecting the kidney during critical illness.

Current Opin Anesth, 20(2): 106-12.

♦**Kamel SK and Wie C (2003):**

Controversial issues in the treatment of hyperkalemia.

Nephro Dial Transpl, 18: 2215- 2218.

♦**Kandoth PW, Agarwal GJ and Dharnidharka VR (1994):**

Acute renal failure in child requiring dialysis therapy.

Indian Pediat, 31(3) 305-9.

♦Katzung BG (2006):

Cardiovascular- renal drugs, Basic and clinical pharmacology, 10th Ed, McGraw Hill.

♦Khilji SA and Khan AH (2004):

Acute renal failure after cardiopulmonary bypass surgery.
JAMC, 16(3): 25- 8.

♦Kliegman RM, Behrman RE and Jenson HB (2008):

Glomerular diseases, Nelson textbook of pediatrics, 18th Ed, p 2163- 4, Saunders.

♦Koch J, Plum J and Grabenensee B (2000):

Prostaglandin E₁: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media.
Nephro Dial Transplant, 15: 43- 9.

♦Kramer BK, Bucher M and Sander P (1997):

Effect of hypoxia on growth factor expression in the rat kidney in vivo.
Kidney International, 51: 444- 447.

♦Laisalmi M, Soikkeli A and Kokki H (2003):

Fluoride metabolism in smokers and non smokers following enflurane anesthesia.
BJA, vol 91, No 6.

♦Lassgigg A, Donner E and Grubhofer (2000):

Lack of renoprotective effects of dopamine and furosemide during cardiac surgery.
J Am Soc Nephrol, 11: 97- 104.

◆Leonard BL and Malpas SC (2000):

Neural regulation of renal blood flow: a reexamination.
CEPP J, vol 27, issue 12, p 956- 64.

◆Mai S, Xu F and Wu T (2005):

Nutritional support for acute renal failure.
Cochrane Database of Systemic Reviews2005, issue 3.

◆Makikallio K (2002):

Atrial natriuretic peptide (ANP).
Circulation, vol 105(17): 2058- 2063.

◆Mannix R, Mei Lin Tan and Wright R (2006):

Acute pediatric rhabdomyolysis: causes and rates of renal failure.
Pediatrics, 118(5): 2119- 2125.

◆Marik PE (2002):

Low dose dopamine: a systemic review.
Int Care Med, 28: 877- 83.

◆Marino PL (2007):

Organic acidoses, In: ICU book, 3rd Ed, Lippincott Williams& Wilkins.

◆Masood M and Mushtaq MA (2006):

Treatment of hyperkalemia with salbutamol and insulin.
Pak J Med Sci, vol 22, no 2.

◆McDonald B, Mehta RL and Gabbai FB (2001):

Collaborative group for treatment of ARF in ICU. A randomized trial
clinical trial of continuous vs intermittent dialysis for ARF.

Kidney Int, 60: 1154- 63.

♦**Mehta RL and Chertow GM (2003):**

ARF definition and classification: a time for change.

J Am Soc Nephrol, 14(8): 2178- 2187.

♦**Miller RD (2005):**

Miller's Anesthesia, 6th Ed, Elsevier comp.

♦**Misioek H, Kucia H and Gumprech J (2006):**

The influence of sevoflurane on renal function during general anesthesia and low flow technique preliminary report.

Ann U Acad U Med U Siles U, vol 60, no 6.

♦**Molitoris BA, Sandoval R and Sutton TA (2002):**

Endothelial injury and dysfunction in ischemic acute renal failure.

Crit Care Med, 30(5): S235- 40.

♦**Moore EW and Hunter JM (2001):**

The new neuromuscular blocking agents: do they offer any advantages?

BJA, vol 87, no 6: 912- 25.

♦**Morgan EG and Mikhail SM (2006):**

The nephron, In: renal physiology & anesthesia, Clinical Anesthesiology, 4th Ed, McGraw Hill.

♦**Naughton CA (2008):**

Drug induced nephrotoxicity.

Am Fam Physician, 15;78(6):743- 50.

◆Neuhofer W and Pittrow D (2006):

Role of endothelin and endothelin receptor antagonists in renal disease.
European J of Clinical investigation, vol 36, suppl 3, p 78- 88.

◆Padillo FJ, Cruz A, Briceno J and Martin MA (2005):

Multivariate analysis of factors associated with renal dysfunction in patients with obstructive jaundice.
BJ of Surgery, vol 92, no 11, p 1388-1392.

◆Phu NH (2002):

Hemofiltration and peritoneal dialysis in infection associated acute renal failure.
New England J of Medicine, 347(12): 895- 902.

◆Piper SN, Kumle B and Matech WH (2003):

Diltiazem may preserve renal tubular integrity after cardiac surgery.
Can J Anesth, 50:285- 92.

◆Porth CM (2005):

Pathophysiology: concepts of altered health state, 7th Ed, Lippincott Williams& Wilkins.

◆Redfors B, Sward K and Sellgren J (2009):

Effects of mannitol alone and mannitol plus furosemide on renal oxygen consumption, renal blood flow and glomerular filtration rate.
Int Care Med, vol 35, issue 1, p 115- 122.

◆Remuzzi G, Ruggenti P and Perico N (2002):

Chronic renal diseases: Renoprotective benefits of renin- angiotensin system inhibition.

Ann Intern Med, 136- 140.

♦**Rivera F and Lopez- Gomez JM (2008):**

Renal biopsy findings in acute renal failure in the Cohort of patients in the Spanish registry of glomerulonephritis.

Clin J Am Soc Nephrol, 3: 674- 681.

♦**Rocca DG, Pompei L and Coccia C (2003):**

Atracurium, cisatracurium, vecuronium and rocuronium in patients with renal failure.

Minerva Anes, 69(7-8): 605- 11, 612,5.

♦**Sadovnikoff N and Gelman S(1999):**

Perioperative renal protection.

Curr Opin ANESTH, 12(3): 337- 41.

♦**Slden R (2008):**

Perioperative renal protection, ASA refresher course lecture.

♦**Saltzman HF, Sharma K and Mather PJ (2007):**

Renal dysfunction in heart failure patients: what is the evidence?

Heart failure reviews, vol 12no 1, 37- 47.

♦**Sarwal MM, Annabelle N and Chua I (2005):**

Acute renal failure management.

Neonate Am Acad of Ped, vol 6, no 8, p 369.

♦**Schlichting D and McCollam JS (2007):**

Recognizing and managing of sever sepsis: Acommon and deadly threat.

Southern Med J, vol 100, no 6.

♦Schrier RW (2007):

Acute renal failure, In : Diseases of the kidney& urinary tract, vol 2, 8th Ed, Lippincott Williams& Wilkins.

♦Schulze A (2007):

Respiratory gas conditioning and humidification.
Clinics in Perinatology, vol 34, issue 1.

♦Sener M, Torgay A and Akpek E (2004):

Regional vs general anesthesia for donor nephrectomy: Effects on graft function.
Transplantation proceedings, vol 36, issue 10, p 2954- 2958.

♦Sheinbaum R, Ignacio C, Safi HJ and Estrera A (2003):

A compensatory strategies to preserve renal function during cardiac and vascular surgery.
Rev Cardiovasc Med, 4(1): 21- 8.

♦Sherwood L (2001):

A Human physiology: from cell to systems. Pacific Grove, 6th Ed, CA: Brooks/ Cole.

♦Stafford- Smith M (2005):

Evidence- based renal protection in cardiac surgery.
Semin Cardiothorac Vasc Anesth, 9(1): 65- 75.

♦Stein HJ (1990):

Regulation of renal circulation.
Kid Intern, 38, 571- 576.

♦Stoelting RK and Dierdorf SF (2002):

Anesthesia and coexisting diseases, 4th Ed, p 341- 65, Churchill Living stone.

♦Stoelting RK and Hillier SC (2006):

Pharmacology and physiology in anesthetic practice, 2nd Ed, vol 1, Lippincott Williams& Wilkins.

♦Szenohradsky J, Fisher DM and Segredo V (2004):

Pharmacokinetics of rocuronium bromide in patients with normal renal function or patients under cadaver renal transplantation.
Revista Mexicana de Anesthiologica, vol 27, no 4, p 196- 199.

♦Tan HK, Bellomo R, M' Pisi DA and Ronco C (2001):

Phosphatemic control during acute renal failure, intermittent hemodialysis vs continuous hemofiltration.
Int J Artif Org, 24:186- 191.

♦Thadhani R, Pascule M and Bonventre JV (1998):

Acute Renal Failure.
N Engl J Med, 334: 1448- 60.

♦Thapa S and Brull SJ (2000):

Succinylcholine induced hyperkalemia in patients with renal failure: An old question revisited.
Anesth Analg, 91: 237- 241.

♦Tisher CC and Mdsen KM (2000):

Anatomy of the kidney, In Brenner BM, Rector FCJ (editors) 4th Ed, 3-75.

♦Tokyuama H, Hayashi k and Matsuda H (2003):

Role of nitric oxide and prostaglandin E₂ in acute renal hypoperfusion.
Nephrology, vol 8, no 2, p 65- 71.

♦Tomer D, Hong JJ and Malcynski JT (2006):

Novel use of acetazolamide in the treatment of rhabdomyolysis induced myoglobinuric renal failure.
Journal of Trauma- Injury Infection& Crit Care 61(1): 213- 215.

♦Tulkens PM and Mingeot- Leclercq MP (1999):

Aminoglycosides nephrotoxicity.
American Society of Microbiology, vol 43, no 5, p 1003- 1012.

♦Ulinski T, Guigonis V, Dunan O and Bensman A (2004):

Acute renal failure after treatment with NSAID_s.
Eur J of Ped, 163: 148- 150.

♦ Van Biesen W, Lameire N and Vanholder R (2005):

Acute renal failure.
Lancet, 365(9457): 417- 30.

♦Venugopal J (2003):

Pharmacologic modulation of the natriuretic peptide system.
Expert Opinion on Therapeutic Patents 13(9): 1389.

♦Villa P, Jimenez M and Soriano M (2005):

Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients.
Crit Care, vol 9: 139- 143.

◆Wesson DE, Bensard DD and Copper A (2006):

Renal failure, In: Pediatric trauma textbook, p 204- 5, CRC press.

◆Whyte DA and Fine RN (2008):

Acute renal failure in children.

Ped in Rev, 29: 299- 307.

◆Williams JS and Williams GH (2003):

50th Anniversary of aldosterone.

J Clin Endoc Metabol, 88(6): 2364- 2372.

◆Yeung E, Yong E and Wong F (2004):

Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Med Gen Med, 6(4):9.

◆Yumpa YP, Sakr Y and Reinhart K (2005):

Has mortality from acute renal failure decreased? A systematic review of the literature.

Am J Med, 118(8): 827- 32.